News

Kwatra spoke at Fall Clinical about several key highlights from his sessions discussing atopic dermatitis, prurigo nodularis, and the OX40 ligand (OX40L).

The FDA has approved Kygevvi (doxycitine and doxribtimine), the first therapy to improve functional outcomes and survival in thymidine kinase 2 deficiency.

Following a Type A meeting with the FDA, the ophthalmic formulation of bevacizumab is back on track towards a potential US approval.

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Following CHEST 2025, Hanania discusses the progress being made toward more tailored, patient-oriented care in airway disorders.

Exposure to nonoptimal temperatures have shown an association with deaths among patients with heart failure.

These phase 4 data from the UnlIMMited trial highlight the efficacy and safety of risankizumab for psoriasis in the genital or scalp region.

Recent research has highlighted the influence of minor beat-to-beat changes in blood pressure on the left side of the brain.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Meta-analysis finds peritoneal and hemodialysis offer similar survival in ESRD.

The interview highlights the evolution of atopic dermatitis treatment, emphasizing options beyond topical steroids.

A recent European study has confirmed prior American data showing the predictive ability of this combination measurement in healthy patients.

Elevated neutrophil-to-lymphocyte ratio predicts early kidney decline in IgA nephropathy.

In this segment of his Fall Clinical interview, Nestor discussed actinic keratosis and shifts in the rates of skin cancer.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Mayo explains findings from a pooled analysis of pruritus data from RESPONSE and ENHANCE highlighting seladelpar’s impact on itch in PBC.

Nestor spoke in this interview about avoiding cosmetic complications and educating patients on available treatments like toxins and fillers.

New data show peanut allergy rates have dropped sharply since early introduction guidelines, reducing 27% and 43% after the 2015 and 2017 guidelines, respectively.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.

In this interview, Swanson highlights the topics covered in her session on oral and injectable medications, and specifically icotrokinra, in the psoriasis pipeline.

Markov model findings showed elafibranor provided greater health benefit at a lower cost than seladelpar in ursodeoxycholic acid incomplete responders.

Addiction treatment evolves by integrating biological health with psychological care, emphasizing a holistic approach for lasting recovery.

Preeclampsia, gestational diabetes, preterm delivery, large for gestational age, and other hypertensive disorders of pregnancy are now risk factors.

Keefer emphasizes the importance of treatment satisfaction and health-related quality of life in IBD and reviews findings from ASPIRE-CD.

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.